SCHEMBL7453176

SCHEMBL7453176

COCCc1cccc2c1ccn2C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
RHEB Q15382 1/20 0.44
ALDH1A1 P00352 2/20 0.41
GPR84 Q9NQS5 1/20 0.41
MAPT P10636 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HDAC6 Q9UBN7 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HTR2A P28223 1/20 0.40
NQO2 P16083 1/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17784695 0.82 HDAC1 (0.43) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL17784718 0.81 HDAC1 (0.44) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL31370592 0.81 HTR2A (0.62) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL8739002 0.78 MAPT (0.46) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL27368360 0.78 HDAC1 (0.40) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL8659188 0.77 HDAC1 (0.39) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL10968328 0.77 HDAC1 (0.39) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL8093101 0.77 HTR2A (0.49) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL1288089 0.77 KDM4E (0.48) KDM4ERHEBALDH1A1GPR84MAPT
SCHEMBL15105484 0.77 KDM4E (0.44) KDM4ERHEBALDH1A1GPR84MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037887-A1 Method for reducing intraocular pressure using indole derivatives UNIVERSIDAD COMPLUTENSE DE MADRID (ES) 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037887-A1 Method for reducing intraocular pressure using indole derivatives MTNR1A, MTNR1B, MC5R KDM4E 1189/4885RHEB 2584/4885ALDH1A1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.